Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Approach to Temperature Control in Cell Therapy Clinical Trial

Published: Wednesday, April 23, 2014
Last Updated: Wednesday, April 23, 2014
Bookmark and Share
CoolCell® cell freezing device and CoolBox™ ice-free cooling workstations chosen to support handling and processing of investigational cell therapy product in landmark clinical research trial.

BioCision, LLC has announced that several of the company’s products used to support temperature control, as well as processing and handling of cell therapy products, will be used in a Phase IIb clinical trial conducted by TxCell.

The trial will investigate the use of Ovasave®, an antigen-specific regulatory T (Ag-Treg) autologous cell-based immunotherapy for the treatment of patients with moderate to severe refractory Crohn’s disease.

In the Ovasave® Phase IIb trial, TxCell, which specializes in developing cell-based therapies for chronic inflammatory disease, will use the BioCision CoolCell® passive cell freezing device as the method for freezing Ag-Treg cells.

In previous Ovasave® trials, TxCell used electronic programmable controlled-rate freezers (CRF) to manage the cell freezing temperature, however, the CoolCell® containers will be used for this trial as they provide a cost-effective alternative to the CRF, with the same freezing efficiency and post-thaw outcomes, while also being significantly less expensive to deploy and maintain.

Regulatory T cells are extremely sensitive and changes in efficacy can occur with variations in temperature and handling regimes. TxCell determined that the BioCision products are suitable for use in their authorized Class B manufacturing facility and, therefore, also chose the BioCision CoolBox™ ice-free cooling workstations to ensure standardized and reproducible handling of the cells during manufacturing. The proprietary CoolBox ice-free cooling technology enables asceptic workflow and uniform sample handling, minimizing risk of temperature fluctuation and contamination.

“BioCision products can help researchers in cellular and regenerative medicine achieve the highest possible standards in sample processing and handling, especially as it relates to standardizing the cell cryopreservation workflow,” said Rolf Ehrhardt, MD, PhD, BioCision CEO. “We are pleased that TxCell has selected BioCision products for the Ovasave® Phase IIb trial, and we look forward to working them and other leaders in regenerative medicine and cell therapy research to advance these promising therapies.”

In October 2012, TxCell has announced publication of complete results of the Phase I/II CATS1 study and presented data from a one-year extension of the study supporting the long term tolerability of Ovasave® in the treatment of patients with moderate to severe refractory Crohn’s disease. The development of Ovasave® involves a proprietary manufacturing process where Ag-Treg cells are isolated from the whole blood of the patient and are then expanded ex vivo before reinjection into that same patient.

“As we advance our promising clinical research program for Ovasave® to a Phase IIb trial, the BioCision product portfolio and technology platform present the ideal range of capabilities and quality standards necessary to help us maintain the essential levels of standardization and control we need to be successful,” said TxCell Arnaud Foussat, Vice President Research and New Products at TxCell.

TxCell will present additional details on the use of CoolCell® containers for cell freezing on April 24, 2014 during Poster Session 1 at the 20th Annual Meeting of the International Society of Cellular Therapy in Paris. The abstract is titled, “Use of a low-cost passive freezing device in the effective cryopreservation and recovery of human regulatory T-cells for use in a cell therapy trial.”

The authors evaluated CoolCell containers as an alternative to the classical controlled-rate freezer, resulting in a new standardized method of cell therapy product cryopreservation and marking an important milestone in the ultimate use of cell therapy in the clinic.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CryoPod™ Takes Top Award at ESBB
Industry-first portable cryogenic biospecimen carrier with data logging capability receives second award for innovation.
Wednesday, October 21, 2015
BioCision Announces FDA Master File Acceptance for ThawSTAR
Submission to accelerate adoption of new point-of-care cell thawing technology.
Thursday, September 10, 2015
BioCision ThawSTAR Wins Top Honor for Innovation and Design
ThawSTAR wins gold from instrument business outlook (ibo) in the laboratory equipment industrial design category.
Thursday, August 27, 2015
BioCision to Develop Controlled-Rate Cell Freezing Systems for Cook Regentec Cell Therapy Vials
BioCision and Cook ink exclusive deal to combine technologies to standardize cell cryopreservation in closed-system vials.
Wednesday, July 29, 2015
BioCision to Collaborate with Celgene Cellular Therapeutics
Companies to collaborate on standardizing and de-risking cell thawing process for a Phase 2 cell therapy for the treatment of diabetic foot ulcers.
Wednesday, June 03, 2015
Brooks Automation, BioCision Announce Equity Investment and Strategic Collaboration
Brooks invests $4 million into BioCision to build strategic alignment in biobanking and sample handling.
Monday, March 24, 2014
BioCision Announces Two New U.S. Patents for Thermo-Conductive Products
New patents awarded for CoolSink® Plate Modules and ThermalTray™ Platforms.
Thursday, June 20, 2013
BioCision’s CoolProduct range now available from SANYO
BioCision, LLC have announced the signing of a product distribution agreement with SANYO E&E Europe BV, SANYO’s biomedical division in Europe. SANYO will be marketing the entire CoolProduct portfolio – a modular system of benchtop laboratory tools based on BioCision’s patented technology for temperature change and control of benchtop biomedical samples.
Wednesday, November 17, 2010
Scientific News
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Newfound Strength in Regenerative Medicine
A promising new approach uses direct mechanical stimulation to repair severely damaged skeletal muscles.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Donor's Genotype Controls the Differentiation of IPS Cells
Pluripotent stem cells derived from different cell types are equally susceptible to reprogramming, indicates a recent study by the University of Helsinki and the National Institute for Health and Welfare, Finland. However, the genotype of the donor strongly influences the differentiation of the stem cell.
Signals That Make Early Stem Cells Identified
Researchers at The Rockefeller University have identified a new mechanism by which cells are instructed during development to become stem cells
Healing Scarred Hearts
Findings suggest stem cells may one day be used to regenerate damaged tissue after heart attack.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!